These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37541393)

  • 1. Can we use old NAFLD data under the new MASLD definition?
    Song SJ; Lai JC; Wong GL; Wong VW; Yip TC
    J Hepatol; 2024 Feb; 80(2):e54-e56. PubMed ID: 37541393
    [No Abstract]   [Full Text] [Related]  

  • 2. Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
    He L; Zheng W; Qiu K; Kong W; Zeng T
    J Hepatol; 2024 Feb; 80(2):e85-e87. PubMed ID: 37827469
    [No Abstract]   [Full Text] [Related]  

  • 3. Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.
    Fukunaga S; Mukasa M; Nakano D; Tsutsumi T; Kawaguchi T
    Clin Mol Hepatol; 2024 Jan; 30(1):121-123. PubMed ID: 38044039
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    J Hepatol; 2024 Jul; 81(1):e20-e21. PubMed ID: 38906627
    [No Abstract]   [Full Text] [Related]  

  • 5. MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
    Di Sessa A; Guarino S; Umano GR; Miraglia Del Giudice E; Marzuillo P
    J Hepatol; 2024 Feb; 80(2):e87-e89. PubMed ID: 37890724
    [No Abstract]   [Full Text] [Related]  

  • 6. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From NAFLD to MASLD: Promise and pitfalls of a new definition †.
    Cusi K; Younossi Z; Roden M
    Hepatology; 2024 Feb; 79(2):E13-E15. PubMed ID: 38112428
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    Hepatology; 2024 Feb; 79(2):E16-E17. PubMed ID: 38112434
    [No Abstract]   [Full Text] [Related]  

  • 10. From NAFLD to MASLD: Promise and pitfalls of a new definition.
    Cusi K; Younossi Z; Roden M
    J Hepatol; 2024 Jul; 81(1):e18-e19. PubMed ID: 38906626
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'.
    Rinella ME; Narro GEC; Krag A; Terrault N; Newsome PN
    Ann Hepatol; 2024; 29(4):101178. PubMed ID: 38944461
    [No Abstract]   [Full Text] [Related]  

  • 12. From NAFLD to MASLD: Promise and pitfalls of a new definition.
    Cusi K; Younossi Z; Roden M
    Ann Hepatol; 2024; 29(4):101179. PubMed ID: 38944463
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    De A; Bhagat N; Mehta M; Taneja S; Duseja A
    J Hepatol; 2024 Feb; 80(2):e61-e62. PubMed ID: 37558135
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease: Definition and subtypes.
    Han SK; Baik SK; Kim MY
    Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.
    Kummer S; Klee D; Kircheis G; Friedt M; Schaper J; Häussinger D; Mayatepek E; Meissner T
    Eur J Pediatr; 2017 Apr; 176(4):529-536. PubMed ID: 28213828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.
    Rinella ME; Sookoian S
    J Lipid Res; 2024 Jan; 65(1):100485. PubMed ID: 38103785
    [No Abstract]   [Full Text] [Related]  

  • 18. Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.
    Wang T; Xi Y; Raji A; Crutchlow M; Fernandes G; Engel SS; Zhang X
    Ann Hepatol; 2024; 29(1):101154. PubMed ID: 37742743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.